Screener
NewAmsterdam Pharma Company NAMS Stockholders Equity
Stockholders Equity at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: NewAmsterdam Pharma Company’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333824
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Commitments and contingencies (Note 12) | ||
| Shareholders' Equity: | ||
| Ordinary shares, €0.12 par value; 400,000,000 shares authorized; 117,651,697 and 114,399,326 shares issued and outstanding as at June 30, 2026 and December 31, 2025, respectively | 14,735 | 14,278 |
| Additional paid-in capital | 1,487,792 | 1,426,750 |
| Accumulated loss | (874,966) | (762,390) |
| Accumulated other comprehensive income | 3,861 | 4,793 |
| Total shareholders' equity | 631,422 | 683,431 |
| Total liabilities and shareholders' equity | 704,452 | 769,284 |
Item 1. Financial Statements.
FAQ
- What is NewAmsterdam Pharma Company's stockholders equity?
- NewAmsterdam Pharma Company (NAMS) reported stockholders equity of $631.42M in Q2 2026.
- How has NewAmsterdam Pharma Company's stockholders equity changed year-over-year?
- NewAmsterdam Pharma Company's stockholders equity decreased by 18.9% year-over-year, from $778.5M to $631.42M.
- What is the long-term trend for NewAmsterdam Pharma Company's stockholders equity?
- Over 5 years (2020 to 2025), NewAmsterdam Pharma Company's stockholders equity has grown at a 56.4% compound annual growth rate (CAGR), from -$73.04M to $683.43M.
- What does stockholders equity mean?
- Stockholders Equity as reported by NewAmsterdam Pharma Company N.V. Ordinary Shares.
Ask your AI about NewAmsterdam Pharma Company's stockholders equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude